Objective: In vivo study was carried out to investigate the effect of
oral glibenclamide on biochemical laboratory findings. Methods: 30 subjects (17
males and 13 females) with an average age of (45 ?16 years) and average weight
(80 ? 18 kg) were participated in this study. They were newly diagnosed with
non-insulin dependent diabetes mellitus. 20 healthy volunteers of comparable
age and weight (47 ? 13 years ; 77 ? 12 kg) were used as control sample. Two
venous blood samples were taken from each subject, first blood sample was taken
before glibenclamide therapy (5 mg/daily) and the second blood sample was taken
14 weeks after drug therapy. The two samples were analysed for glucose, HbA1c,
total cholesterol, Triglyceride, LDL and HDL. Results: At week 14,
glibenclamide treatment resulted in significantly greater reduction in both
HbA1c and fasting plasma glucose (p < 0.05). Triglyceride as well as HDL
were significantly increased. Conclusion: glibenclamide treatment for 14 weeks
is effective in reducing significantly fasting blood sugar and HbA1c and it has
positive effect in raising the level of HDL. - See more at:
No comments:
Post a Comment